ArticleDiabetology & metabolic syndrome2026
miR-4687-5p promotes the progression of diabetic retinopathy by targeting SIRT2 to mediate inflammatory responses.
Article in Diabetology & metabolic syndrome, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
aimsTo investigate the role and underlying mechanisms of miR-4687-5p in diabetic retinopathy (DR) development.
methodsA total of 180 DR patients were enrolled and stratified into non-proliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR) groups. Concurrently, 100 type 2 diabetes mellitus (T2DM) patients and 100 healthy volunteers were recruited as control groups. DR cellular models were established by treating ARPE-19 cells with high glucose (HG). Reverse transcription quantitative polymerase chain reaction was used to detect gene expression. An in vitro DR cell model was constructed to explore the potential mechanism of miR-4867-5p in DR.
resultsSerum miR-4687-5p expression was significantly elevated in DR patients compared to healthy controls and T2DM patients, with the highest levels observed in PDR patients. This miRNA exhibited excellent diagnostic value for DR. miR-4687-5p expression positively correlated with clinical parameters and pro-inflammatory cytokines in DR patients. In DR cell models, miR-4687-5p overexpression inhibited cell viability, promoted apoptosis, and exacerbated inflammatory responses, whereas miR-4687-5p knockdown exerted opposite effects. Mechanistically, miR-4687-5p contributes to DR progression by negatively regulating SIRT2 to modulate cell function and inflammation.
conclusionsmiR-4687-5p is expected to become a biomarker for the early diagnosis of DR and a potential therapeutic target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.